300003 Lepu Medical Technology
- 15.93
- -0.12-0.75%
Lepu Medical Technology News
Two self-developed products from Lepu Medical (300003.SZ) subsidiary companies received NMPA registration approval
Lepu Medical (300003.SZ) announced that the company's subsidiary, Sichuan Xingtai Pule Medical Technology Co., Ltd. independently researched...
Lepu Medical (300003.SZ): Radiofrequency puncture generator obtained NMPA registration approval
Gelonghui announced on May 6 | Lepu Medical (300003.SZ). The company recently learned that the radiofrequency puncture generator independently developed by its subsidiary Shanghai Shape Memory Alloy Material Co., Ltd. has obtained registration approval from the National Drug Administration (NMPA). Approval number: Guojian Note 20243010854.
Lepu Medical (300003.SZ) announced its 2023 annual results, net profit of 1,258 billion yuan, and plans to distribute 10 to 3.3141 yuan
Lepu Medical (300003.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 7...
Lepu Medical (300003.SZ): 0.53% of shares have been repurchased cumulatively
Gelonghui, April 3, 丨 Lepu Medical (300003.SZ) announced that as of March 29, 2024, the company had repurchased a total of 9,962,200 shares of the company's shares through a dedicated securities account, accounting for 0.53% of the company's latest total share capital. The highest transaction price was 16.65 yuan/share, the minimum transaction price was 12.18 yuan/share, and the total transaction amount was 149.304 million yuan (excluding transaction fees).
Lepu Healthcare (300003.SZ): A total cost of 149.9 billion yuan to repurchase 9.622 million shares
Gelonghui, March 4, 丨 Lepu Medical (300003.SZ) announced that as of February 29, 2024, the company had repurchased 9.622 million shares of the company's shares through a dedicated securities account, accounting for 0.53% of the company's latest total share capital. The highest transaction price was 16.65 yuan/share, the minimum transaction price was 12.18 yuan/share, and the total transaction amount was 149.9 million yuan (excluding transaction fees).
Southwest Securities: There is still a lot of room for penetration in the coronary artery disease interventional treatment market, focus on Sano Healthcare (688108.SH), etc.
Coronary heart disease is the leading cause of death in the world, and there is still plenty of room for penetration in the interventional treatment market for coronary artery disease in China.
Lepu Medical (300003.SZ): Subsidiary companies intend to win the bid for clopidogrel bisulfate tablets, atorvastatin calcium tablets, and rosofastatin calcium tablets to win the bid for Guangdong Union Drug Collection
Gelonghui, Feb. 1, 丨 Lepu Medical (300003.SZ) announced that on January 31, 2024, the company learned that its subsidiaries Lepu Pharmaceutical Co., Ltd. and Lepu Pharmaceutical Technology Co., Ltd. participated in the bidding process for centralized volume procurement of drugs such as amoxicillin in Guangdong Union, and that they have passed the consistent evaluation of generic drug quality and efficacy, to win the bid for this centralized procurement. The above product companies all have their own raw materials.
Lepu Healthcare (300003.SZ): A total cost of 132 million yuan to buy back 8.5722 million shares
Gelonghui, February 1, 丨 Lepu Medical (300003.SZ) announced that as of January 31, 2024, the company had repurchased 8.572,200 shares of the company's shares through a dedicated securities account, accounting for 0.46% of the company's latest total share capital. The highest transaction price was 16.65 yuan/share, the minimum transaction price was 13.12 yuan/share, and the total transaction amount was 132 million yuan (excluding transaction fees).
Lepu Medical (300003.SZ): Coronary mastoid balloon dilatation catheter obtained NMPA registration approval
Gelonghui, January 22丨Lepu Medical (300003.SZ) announced today that the company's self-developed coronary mastoid balloon dilatation catheter was officially approved by the National Drug Administration (NMPA) and obtained a Class III medical device registration certificate. Registration certificate number: National Machinery Note 20243030105. The coronary mastoid balloon dilatation catheter is one of the important methods for dilating a narrow part of the coronary artery. Rows of mastoid processes are distributed on its surface. During high-pressure dilation, these mastoid processes can fracture hard plaques, and stay stably in the corresponding position during expansion to avoid sliding. After placing the stand
Lepu Medical (300003.SZ): A next-generation insulin plan has not yet been laid out
Gelonghui, January 22丨An investor asked Lepu Healthcare (300003.SZ) on the investor interactive platform, “Does the company currently have plans to develop next-generation insulin?” The company replied that the company has not yet laid out a next-generation insulin plan.
Lepu Medical (300003.SZ): Single-use coronary intravascular shock wave catheters obtained NMPA registration approval
Gelonghui, January 10 | Lepu Medical (300003.SZ) announced that the company learned today that the single-use coronary intravascular shock wave catheter independently developed by the company has officially obtained registration approval from the National Drug Administration (NMPA) and obtained a Class III medical device registration certificate. Registration certificate number: National Machinery Note 20243010074.
Lepu Medical (300003.SZ): Insulin glargine has been approved for marketing
Gelonghui, January 9丨An investor asked Lepu Healthcare (300003.SZ) on the investor interactive platform, “How long is it expected to take to obtain the insulin approval?” The company replied that the company's insulin glargine had been approved for marketing.
Lepu Medical (300003.SZ): A total cost of 75.2365 million yuan to buy back 4.6987 million shares
Gelonghui, January 2, 丨 Lepu Medical (300003.SZ) announced that as of December 31, 2023, the company had repurchased 4.698,700 shares of the company's shares through a dedicated securities account, accounting for 0.25% of the company's latest total share capital. The highest transaction price was 16.65 yuan/share, the minimum transaction price was 15.65 yuan/share, and the total transaction amount was 75.2365 million yuan (excluding transaction fees).
PW Medtech Renews Purchase Deal With Lepu Medical
PW Medtech Group (HKG:1358) renewed its agreement with Lepu Medical (SHE:300003) for the purchase of medical devices molds and components worth up to 10 million yuan (HK$11.3 million), according to a
Shengnuo Biology (688117.SH): The holdings reduction period has expired, and Lepu Medical has reduced its holdings by 2.5987% of the company's shares
On December 8, Gelonghui (688117.SH) announced that the company recently received the “Notice Letter on the Results of Share Reduction” issued by Lepu Medical. As of the disclosure date of this announcement, Lepu Medical has reduced its holdings of the company's shares by a total of 1,108,055 shares through centralized bidding, accounting for 0.9893% of the company's total share capital; it has reduced its holdings of 1,802,500 shares through bulk transactions, accounting for 1.6094% of the company's total share capital. After reducing its holdings, the number of shares held by LePu Medical was 6,161,445 shares, accounting for 5.5013% of the company's total share capital. This time
Lepu Medical (300003.SZ): Glicin insulin injection obtained NMPA registration approval
Gelonghui announced on December 8, Lepu Healthcare (300003.SZ). The company learned today that the insulin injection of glycine independently developed by its subsidiary, Liaoning Boao Biopharmaceutical Co., Ltd., has been officially approved for registration by the State Drug Administration (NMPA). Drug approval number: S20230067, China Pharmaceutical Standard. Insulin glycine is a long-acting insulin analogue produced through genetic recombination technology. It can control fasting blood sugar safely, stably, and for a long time and reduce the incidence of hypoglycemia. The successful approval of the company's insulin glargine injection marks that the company has achieved important results in the field of blood sugar control, further enriching it
Lepu Healthcare (300003.SZ): The initial repurchase of 780,000 shares involved 129.59 million yuan
Glonghui on December 5 | Lepu Healthcare (300003.SZ) announced that on December 5, 2023, the company first repurchased 780,000 shares of the company through a special repurchase account through centralized bidding transactions, accounting for 0.0415% of the company's total share capital. The maximum transaction price was 16.65 yuan/share, the lowest transaction price was 16.58 yuan/share, and the total transaction amount was 129.59 million yuan (excluding transaction fees).
Lepu Bio-B and Lepu Healthcare enter into CDMO service framework agreement
Lepu Bio-B (02157) announced that on November 13, 2023, the company entered into a CDMO service framework agreement with Lepu Healthcare. The company and/or its subsidiaries agreed to provide CDMO technical services to Lepu Medical and/or its subsidiaries. The Group is mainly engaged in the research and development of its drug candidates and operates a bioreactor production line that complies with GMP standards. The production line has been in operation since the end of 2019.
Lepu Bio-B (02157.HK) and Lepu Healthcare enter into CDMO service framework agreement
Gelonghui, November 13|Lepu Biotech - B (02157.HK) announced that on November 13, 2023, the company and Lepu Healthcare entered into a CDMO service framework agreement. According to this, the company and/or its subsidiaries agreed to provide CDMO technical services to Lepu Medical and/or its subsidiaries.
[BT Financial Report Instantaneous Analysis] Lepu Healthcare's 2023 Quarterly Report: Net profit and operating income have both declined, net cash flow has declined sharply, and future development is still worth looking forward to
This financial report was announced on 2023-10-25 18:24:35 Lepu Healthcare (stock code: 300003) is a full-life cycle solution provider focusing on cardiovascular diseases. Its business segments include medical devices, pharmaceuticals, medical services and health management. The company adheres to the medium- to long-term strategy of “innovation, consumption and internationalization” and achieves long-term steady business development through multi-wheel drive. In a context where the overall development trend of China's medical device industry is improving and the domestic replacement rate is constantly increasing, Lepu Medical has seized good market opportunities. In terms of assets and liabilities, Lepu Healthcare 202
Analysis
Price Target
No Data
